Immunovascular antibody PC-mAb reduces vein graft remodeling in preclinical study
Stockholm April 23, 2018 Scientists from Leiden University Medical Center and the biotech company Athera report study data at the 5th congress of Frontiers in Cardiovascular Biology (FCVB). The congress is organized in Vienna by the European Cardiovascular Society (ESC). The preclinical in vivo study concluded that PC-mAb effectively inhibits adverse vein graft remodeling and intraplaque angiogenesis. They suggest that the fully human PC-mAb holds promise as a new therapeutic approach to prevent vein graft disease.
The clinical stage antibody PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC (phosphorylcholine) and act to alleviate the immune response to vascular inflammation challenges and thereby reduce the risk for complications. Revascularization by vein graft surgery in the legs of patients with severe peripheral arterial disease, PAD, is done to restore blood flow, to reduce pain and restore mobility. However, the risk for subsequent amputation of the affected limb is still high, as well as severe events like heart attack and stroke. The potential to inhibit inflammation after vein graft surgery in PAD patients by PC-mAb treatment is supported by the conclusions in this preclinical study.
For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB
Phone: +46 (0)76 1938 190, email: email@example.com
Läs mer på MyNewsDesk